REG - Polarean Imaging PLC - Xenon MRI featured prominently at ATS 2025

Polarean ImagingAnnouncement

15/05/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250515:nRSO8739Ia&default-theme=true

RNS Number : 8739I  Polarean Imaging PLC  15 May 2025

 

Polarean Imaging plc

("Polarean" or the "Company")

 

Xenon MRI featured prominently at ATS 2025 across broad clinical spectrum

30+ studies across diverse conditions illuminate the unique value of
functional lung imaging with Xenon MRI

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung
function, will be featured at the American Thoracic Society's (ATS) 2025
Respiratory Innovation Summit (RIS), taking place May 16-17 at the Marriott
Marquis in San Francisco, California. Polarean will also attend the ATS 2025
International Conference from May 18-21, continuing its active engagement with
leaders across pulmonary medicine.

 

Polarean's selection as a featured company at RIS 2025 underscores the growing
recognition of the company's Xenon MRI platform as an innovative tool for both
clinical imaging and pharmaceutical drug development. RIS brings together key
innovators, investors, clinicians, and patient advocacy groups for
cross-sector dialogue on the future of respiratory care.

 

At the ATS 2025 International Conference, Xenon MRI will be featured in over
30 posters and presentations from more than 10 leading clinical sites. This
robust presence reinforces the sustained momentum behind Xenon MRI as a
powerful and enduring technology in pulmonary medicine. The breadth and depth
of research presented this year further demonstrate its expanding role in both
clinical care and clinical trials - signaling that Xenon MRI is not just
innovative, but a lasting part of the respiratory care landscape.

 

The presentations listed below will highlight Xenon MRI's versatility across a
wide spectrum of respiratory conditions, including asthma, bronchopulmonary
dysplasia, COPD, COVID-19, cystic fibrosis, pulmonary arterial hypertension,
radiation-induced lung injury, and post-transplant lung monitoring.

 

Polarean representatives will be on-site throughout RIS and the ATS
International Conference to connect with clinicians, researchers, industry
partners, and patient advocates. As excitement continues to build around
functional lung imaging, Polarean remains at the forefront - visualizing
hidden disease, personalizing treatment, and accelerating the future of
respiratory medicine.

 

Christopher von Jako, PhD, CEO of Polarean, said: "We are honoured to return
as a featured company at the Respiratory Innovation Summit. RIS and the ATS
International Conference provide vital opportunities to engage with thought
leaders, strengthen partnerships, and highlight the growing body of clinical
evidence supporting Xenon MRI. With over 30 presentations this year, it's
clear that Xenon MRI is not only gaining traction-it's shaping the future of
functional lung imaging and respiratory care."

 

See the listing below for details on the presentation title, abstract number,
session time, and location.

Enquiries:

 

 Polarean Imaging plc                                              www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer              Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                                   +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR            Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Paul McManus / Marcus Ulker

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

 

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW®, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 12 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.XENOVIEW.net
(http://www.XENOVIEW.net)

 

 

 

 

 ATS Abstract Title                                                              Presentation Time     Format             Session Location                                                   Clinical Focus Area
 Distinguishing Dose-dependent Radiation Lung Injury Using Hyperpolarized 129Xe  May 18, 2025          Poster Board       Area G, Hall F (North Building, Exhibition Level), Moscone Center  Radiation Induced Lung Injury (RILI)
 Magnetic Resonance Spectroscopy
11:30 AM - 1:15 PM
# P893
 129Xe Gas Exchange MRI in Obesity-associated Asthma: Clinical Correlates and    May 18, 2025          Poster Board       Area G, Hall F (North Building, Exhibition Level), Moscone Center  Asthma
 Regional Patterns
11:30 AM - 1:15 PM
# P873
 Same-session Repeatability of 129Xe MRI/MRS Measures of Gas Exchange in         May 18, 2025          Poster Board       Area G, Hall F (North Building, Exhibition Level), Moscone Center  Idiopathic Pulmonary Fibrosis (IPF)
 Idiopathic Pulmonary Fibrosis
11:30 AM - 1:15 PM
# P885
 Assessment of Regional Ventilation by Hyperpolarized 129Xe MRI in Patients      May 18, 2025          Poster Board       Area G, Hall F (North Building, Exhibition Level), Moscone Center  Asthma, Idiopathic Pulmonary Fibrosis (IPF)
 With Idiopathic Pulmonary Fibrosis and Asthma
11:30 AM - 1:15 PM
# P894
 Regional Patterns of Obstruction and Air-trapping Before and After              May 18, 2025          Poster Board       Room 3010/3012 (West Building, Level 3),                           Asthma
 Exacerbation in Severe Asthma
2:15 PM - 4:15 PM
# 503
Moscone Center
 Utilizing Hyperpolarized 129Xe MRI as a Biomarker for Asthmatics on Biologic    May 18, 2025          Poster Board       Room 3010/3012 (West Building, Level 3),                           Asthma
 Treatments
2:15 PM - 4:15 PM
# 506
Moscone Center
 Investigating the Effects of Vaping on Lung Structure-Function With 129Xe MRI   May 19, 2025          Poster Board       Room 3009/3011 (West Building, Level 3),                           Vaping
 and CT
9:15 AM - 11:15 AM
# 924
Moscone Center
 Data-Efficient Lung Segmentation Using Foundational Models: Improving Clinical  May 19, 2025          Poster Board       Room 3009/3011 (West Building, Level 3),                           Clinical Workflow
 Workflow With Segment Anything Model (SAM) for Hyperpolarized Gas MRI
9:15 AM - 11:15 AM
# 909
Moscone Center
 Mapping the Chemical Shift of 129Xe in Red Blood Cells as a Biomarker for       May 19, 2025          Poster Board       Room 301-302 (South Building, Level 3),                            Pulmonary Hypertension (PH)
 Pulmonary Hypertension
9:15 AM - 11:15 AM
# 407
Moscone Center
 Hyperpolarized 129Xe MRI Captures Elevated Regional Ventilation Heterogeneity   May 19, 2025          Poster Board       Area C, Hall F (North Building, Exhibition Level), Moscone Center  Hematopoietic Stem Cell Transplantation (HSCT), Bronchiolitis Obliterans
 in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic
9:15 AM - 4:15 PM
# P341                                                                               Syndrome (BOS)
 Stem-cell Transplantation in Children
 Xenon Gas Magnetic Resonance Imaging to Characterize Viable Regions of          May 19, 2025          Poster Board       Area B, Hall F (North Building, Exhibition Level), Moscone Center  Endobronchial Valves (EBV)
 Ventilation and Perfusion Prior to Removal of Endobronchial Valves
9:15 AM - 4:15 PM
# P141
 Xe MRI Imaging Findings in the TRANSPIRE Cohort                                  May 19, 2025         Mid-day Symposium  Room 3000/3002/3004 (West Building, Level 3), Moscone Center       Hematopoietic Stem Cell Transplantation (HSCT)

12:48 PM - 1:00 PM
 Exploring the Impact of Inflammation on Gas Exchange Efficiency in              May 19, 2025          Mini Symposium     Room 2005/2007 (West Building, Level 2),                           Cannabis Smoking
 Cannabis-smoking Individuals Using 129XeMRI
4:03 PM - 4:15 PM
Moscone Center
 Characterization of Pulmonary Dysfunction in Children With Systemic Juvenile    May 20, 2025          Poster Board       Room 3009/3011 (West Building, Level 3),                           Systemic Juvenile Idiopathic Arthritis (sJIA)
 Idiopathic Arthritis Using Xe MRI
9:15 AM - 11:15 AM
# 901
Moscone Center
 Single-breath Fractional Ventilation Derived From 129Xe MRI: Repeatability in   May 20, 2025          Poster Board       Room 3009/3011 (West Building, Level 3),                           Idiopathic Pulmonary Fibrosis (IPF)
 Idiopathic Pulmonary Fibrosis
9:15 AM - 11:15 AM
# 920
Moscone Center
 Hyperpolarized129Xe MRI Membrane Uptake Associates With 12-month Changes in     May 20, 2025          Poster Board       Room 2002/2004 (West Building, Level 2),                           Idiopathic Pulmonary Fibrosis (IPF)
 Lung Function in Patients With Idiopathic Pulmonary Fibrosis Initiating
9:15 AM - 11:15 AM
# 616
Moscone Center
 Therapy
 Lung Volume Correction Increases Repeatability of 129Xe Gas Exchange MRI in     May 20, 2025          Poster Board       Room 3009/3011 (West Building, Level 3),                           Idiopathic Pulmonary Fibrosis (IPF)
 IPF
9:15 AM - 11:15 AM
# 919
Moscone Center
 Dynamic Imaging of Physiological Dead Space and Effective Alveolar Ventilation  May 20, 2025          Poster Board       Area C, Hall F (North Building, Exhibition Level), Moscone Center  Endobronchial Valves (EBV)
 in Patients Undergoing Endobronchial Valve Therapy Using Hyperpolarized Xenon
11:30 AM - 1:15 PM
# P357
 Image-guided Bronchoscopy in Severe Asthma Reveals Inflammatory and Epithelial  May 20, 2025          Poster Board       Room 213-214 (South Building, Level 2),                            Asthma
 Remodeling in Post-exacerbation Ventilation Defects
2:15 PM - 4:15 PM
# 301
Moscone Center
 Pulmonary 129Xe Ventilation MRI Predicts Severe Exacerbations in People With    May 20, 2025          Mini Symposium     Room 211-212 (South Building, Level 2),                            Cystic Fibrosis (CF)
 CF
2:39 PM - 2:51 PM
Moscone Center
 MRI-based Ventilation-perfusion (V/Q) Matching Using Hyperpolarized Xenon and   May 21, 2025          Poster Board       Room 2002/2004 (West Building, Level 2),                           Long-COVID
 Dynamic Contrast-enhanced MRI in Long COVID Patients
8:15 AM - 10:15 AM
# 609
Moscone Center
 Analyzing the Impact of Fitted Transit Time on Simulated Alveolar Septal Wall   May 21, 2025          Poster Board       Room 2002/2004 (West Building, Level 2),                           Cellular Mechanisms
 Thickness Measurements With Hyperpolarized Xenon-129 MRI
8:15 AM - 10:15 AM
# 621
Moscone Center
 Assessment of Dyspnea of Unknown Origin With Hyperpolarized Xenon-129 Gas MRI:  May 21, 2025          Poster Board       Room 207-208 (South Building, Level 2),                            Unexplained Dyspnea
 A Case Series
8:15 AM - 10:15 AM
# 202
Moscone Center
 Pulmonary Regional Differences Highlight Profibrotic Airway Epithelial Cell     May 21, 2025          Mini Symposium     Room 3014/3016/3018 (West Building, Level 3), Moscone Center       Asthma
 Signaling in Obese Asthma
9:15 AM - 9:27 AM
 Continued Lung Ventilation Improvement in People With Cystic Fibrosis           May 21, 2025          Mini Symposium     Room 3006/3008 (West Building, Level 3),                           Cystic Fibrosis (CF)
 Receiving Highly Effective Modulator Therapy
9:39 AM - 9:51 AM
Moscone Center
 Precision Imaging Meets Lung Transplantation: Hyperpolarized Gas Magnetic       May 21, 2025          Poster Board       Room 3022/3024 (West Building, Level 3),                           Lung Transplantation
 Resonance Imaging and Transcriptomic Signatures Transform Rejection Detection
11:00 AM - 1:00 PM
# 1018
Moscone Center
 Assessing Post-Transplant Lung Function Alterations Using Free-Breathing        May 21, 2025          Poster Board       Room 301-302 (South Building, Level 3),                            Lung Transplantation
 Hyperpolarized Xenon MRI
11:00 AM - 1:00 PM
# 401
Moscone Center
 Comparison of Healthy Reference Models for 129Xe Pulmonary Gas Exchange         May 21, 2025          Poster Board       Room 301-302 (South Building, Level 3),                            Healthy Lung

11:00 AM - 1:00 PM
# 403
Moscone Center
 XeLHC: Initial Impressions From Hyperpolarized 129Xe MRI Measurements of        May 21, 2025          Poster Board       Room 301-302 (South Building, Level 3),                            Healthy Lung
 Regional Lung Health in Participants From the Lung Health Cohort
11:00 AM - 1:00 PM
# 408
Moscone Center
 Multi-site Analysis of Functional Gas Exchange Measures on 129Xe MRI Among      May 21, 2025          Poster Board       Room 301-302 (South Building, Level 3),                            Healthy Lung
 Healthy Volunteers
11:00 AM - 1:00 PM
# 411
Moscone Center
 The Age-dependent Upper Limit of Normal for Hyperpolarized 129Xe MRI            May 21, 2025          Poster Board       Room 301-302 (South Building, Level 3),                            Healthy Lung
 Ventilation Defect Percent in Healthy Individuals Using a Multi-center
11:00 AM - 1:00 PM
# 421
Moscone Center
 Database
 Multifunctional Xe MRI to Assess Alveolar Microstructure and Gas-exchange in    May 21, 2025          Mini Symposium     Room 3006/3008 (West Building, Level 3),                           Lymphangioleio-myomatosis (LAM)
 Women With Lymphangioleiomyomatosis
11:48 AM - 12:00 PM
Moscone Center

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFSFFIEISELI